AIDX — 20/20 Biolabs, Inc.

Nasdaq · Unknown · Unknown · CIK 1139685 ·
Last close
$1.02
Market Cap
$10.69M
52W High
$3.99
52W Low
$0.90
ADV30
384,306
Next earnings
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Dec 2025 538,274 130,417 -912,846 -1,307,771 4,137,357 1,025,987 4,156,582
Sep 2025 3,239,449 1,144,855 3,130,993
Dec 2024 536,084 163,030 -1,243,998 -1,249,048 3,584,408 1,784,009 2,078,926

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-1,048,118
Investing CF
Financing CF
$502,825
CapEx
Dividends Paid
Buybacks
EPS Diluted TTM
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-33,247,219
Inventory
$116,217
Receivables
$199,954
ST Investments
EBIT TTM
$-2,431,834
Pretax Income TTM
$-2,556,819
Interest Exp TTM
$124,985
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,844,688
EBITDA
$-3,921,809
Free Cash Flow
$-1,301,893
Enterprise Value
$7,309,924
Total Cash
$4,219,099
Total Debt
$925,487
Shares Out
10,480,089
Trailing EPS
$-0.36
Book Value
$-0.01
ROE
-241.6%
ROA
-58.9%
Div Yield

Annual Trend (SEC EDGAR, last 3y)

Revenues vs Net Income (last 3y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 2,045,133 -3,330,871 -3,738,821 4,137,357 4,156,582 -1,919,720
Dec 2024 1,752,343 -5,661,057 -5,551,667 3,584,408 2,078,926 -2,598,785
Dec 2023 1,424,304 -6,361,462 -6,391,309 6,367,828 2,080,336 -4,479,971

News headlines (Yahoo Finance, 1h cache)

20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand
2026-05-22 12:31 · Yahoo
20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress
2026-05-20 20:05 · Yahoo
Sidoti Events, LLC's May Micro-Cap Virtual Conference
2026-05-20 11:30 · Yahoo
20/20 BioLabs to Attend Sidoti Micro-Cap Virtual Conference on May 20, 2026
2026-05-14 12:31 · Yahoo
20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South Carolina
2026-05-12 12:31 · Yahoo
HEALWELL to Participate in Upcoming 2026 Bloom Burton & Co. Healthcare Investor Conference
2026-04-13 11:00 · Yahoo
BIO-key International, 20/20 Biolabs, Society Pass, and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
2026-04-10 14:00 · Yahoo
20/20 BioLabs Selected by Evexia Diagnostics to Offer OneTest™ for Cancer Through Evexia Platform
2026-04-07 12:31 · Yahoo
20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress
2026-03-31 20:57 · Yahoo
Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood Test
2026-03-27 12:31 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.